Session Details
Structure-activity relationship/Middle-molecule drugs/Screening
Fri. Mar 29, 2024 3:30 PM - 4:30 PM JST
Fri. Mar 29, 2024 6:30 AM - 7:30 AM UTC
Fri. Mar 29, 2024 6:30 AM - 7:30 AM UTC
[Room 413] Conference Center 413 (4F)
Chair: Taketo Uchiyama, Akio Ojida
[29-413-pm11S]Efficient structural development of hydrophobic moiety in progesterone receptor (PR) ligands using hydroboration of vinylsilanes
○Nao Namba1, Hiroyuki Kagechika1, Shinya Fujii1 (1. Institute of Biomedical and Bioengineering, Tokyo Medical and Dental University)
[29-413-pm12S]Identifying the absolute configuration of the most potent isomer of tryptolinamide as a phosphofructokinase-1 inhibitor
○Ryo Kakehi1, Hiroki Kobayashi2,3, Haruna Nishimura2, Tatsuo Yajima1, Minoru Yoshida2,4, Yasuo Nagaoka1, Takaaki Sumiyoshi1 (1. Dept. Life Sci. & Tech., Kansai Univ., 2. RIKEN CSRS, 3. Tokyo Univ. Pharm. Life Sci., 4. Dept. Biotechnol., Univ. Tokyo.)
[29-413-pm13]Creation of antiviral G quadruplex RNA oligomers
○Shusuke Kuge1 (1. Faculty of Pharm. Sci., Tohoku Med. Pharm. Univ.)
[29-413-pm14S]Development of peptide-PROTACs based on stapling by an E3 ligand
○Hiroaki Kawanami1, Yuri Takada1, Yasunobu Yamashita1, Yukihiro Itoh1, Takayoshi Suzuki1 (1. SANKEN, Osaka Univ.)
[29-413-pm15S]Discovery study on CBX7 inhibitors based on peptide library construction and screening
○Ibuki Yamazaki1, Yuri Takada1, Yasunobu Yamashita1, Yukihiro Itoh1, Takayoshi Suzuki1 (1. SANKEN, Osaka University)
